Pharmspective Launches AccessAI Market Access Artificial Intelligence Platform
By PR Newswire
First of its' kind AI tool ready to replace legacy approaches to secondary research and knowledge acquisition about the Market Access landscape
ST. LOUIS, Nov. 8, 2023 /PRNewswire/ -- Pharmspective LLC announced today the introduction of AccessAI™, the first artificial intelligence (AI) tool built to simplify the acquisition of Market Access knowledge for the biopharmaceutical industry.
AccessAI™ (https://access-ai.net/) has a foundation of over 12,000 references curated and vetted from hundreds of data sources (updated daily) that discuss commercial and government insurers, reimbursement, delivery channels, distribution, payment models, policy, and access and coverage dynamics that impact pharmaceutical manufacturers. AccessAI™ integrates AI technology with expert knowledge that is updated daily to provide on-demand research into market access challenges facing pharmaceutical decision makers.
"AccessAI™ provides a long-overdue solution to dated secondary research approaches that are inefficient and less than cost-effective in acquiring answers to important market access questions," said Nicole Espinoza, Vice-President, Knowledge Management. "Market access knowledge acquisition is ideal for leveraging recent advances in AI to deliver research faster and more accurately."
AccessAI™ is available as a web-enabled, subscription-based portal similar to the simple interfaces associated with standard AI platforms. To support AccessAI™, the company has enlisted a dedicated Content Management team that will help clients maximize the platform's value across Payer Insights teams, Account Management organizations, Payer Marketing groups, and Access Strategy units.
"AccessAI™ is a prime example of how to use AI chatbots for maximum efficiency," stated Laurie Blunt, Director of Content Acquisition. "By connecting AccessAI™'s generative content capability to credible, high-quality market access data sources, we can produce exceptional market research at a fraction of the time and cost of traditional secondary research approaches."
Healthcare companies can contact Pharmspective about AccessAI™ by emailing:
Pharmspective is a Healthcare Knowledge Management Company. Pharmspective currently markets AccessAI™, a first-of-its'-kind Market Access Artificial Intelligence tool that answers questions about the market access and reimbursement landscape across the Healthcare Ecosystem, HealthPlanView™, a novel payer analytics platform providing a multi-stakeholder cost perspective, and PolicyView™, a medical policy analyzer of over 5,000 specialty drug medical policies. We simplify understanding of the Healthcare Ecosystem with cutting edge technologies that clarify the evolving healthcare landscape and move beyond legacy approaches to understanding the payer landscape.
First published on Wed, Nov 8, 2023
Enjoyed what you've read so far? Great news - there's more to explore!
Stay up to date with the latest news, a vast collection of tech articles including introductory guides, product reviews, trends and more, thought-provoking interviews, hottest AI blogs and entertaining tech memes.
Plus, get access to branded insights such as informative white papers, intriguing case studies, in-depth reports, enlightening videos and exciting events and webinars from industry-leading global brands.
Dive into TechDogs' treasure trove today and Know Your World of technology!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs’ members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs’ Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. All information / content found on TechDogs’ site may not necessarily be reviewed by individuals with the expertise to validate its completeness, accuracy and reliability.
Join The Discussion